Nektar Therapeutics (NKTR) vs Rapport Therapeutics (RAPP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Rapport Therapeutics (RAPP) has outperformed Nektar Therapeutics (NKTR) over the past year, gaining 10.3% versus a loss of 27.9%. Rapport Therapeutics is the larger company by market cap ($1.43 billion vs $1.39 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NKTR | RAPP |
|---|---|---|
| Share price | $40.80 | $29.85 |
| Market cap | $1.39B | $1.43B |
| 1-day change | +1.34% | -3.27% |
| YTD return | -3.50% | -1.62% |
| 1-year return | -27.86% | +10.31% |
| 5-year return | -84.29% | — |
| EPS (TTM) | $-18.96 | $-3.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-111.48M |
| 52-week high | $109.00 | $52.93 |
| 52-week low | $33.40 | $23.75 |
| Distance from 52-week high | -62.57% | -43.60% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +246.57% | +111.19% |
| Average volume | 1.07M | 359.60K |
| Shares outstanding | 34.14M | 47.98M |
| Employees | 63 | 84 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RAPP has outperformed NKTR by 38.2 percentage points over the past year.
About Nektar Therapeutics
NKTR stock →Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 63 employees
About Rapport Therapeutics
RAPP stock →Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder.
Health Care · Biotechnology: Pharmaceutical Preparations · 84 employees
NKTR vs RAPP FAQ
Which is bigger, Nektar Therapeutics or Rapport Therapeutics?
Rapport Therapeutics (RAPP) is larger, with a market capitalization of $1.43B compared with $1.39B for Nektar Therapeutics (NKTR).
Which stock has performed better over the past year, NKTR or RAPP?
RAPP returned +10.31% over the past 12 months, compared with -27.86% for NKTR (price return, excluding dividends). Past performance does not predict future results.
Are Nektar Therapeutics and Rapport Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.